Samantha Budd Haeberlein is a distinguished graduate of the University of Dundee having obtained a First Class BSc (Hons) in Biochemistry (1990-94) followed by a PhD in Biochemistry (1994-97). She conducted her PhD studies in the laboratory of Professor David G. Nicholls FRS at the College of Medicine in Dundee where she investigated the role of bioenergetics in neuronal survival and published 10 papers. Following this she conducted post-doctoral research at Brigham and Women’s Hospital and Harvard Medical School in Boston and then at the Burnham Institute in San Diego before joining the biopharmaceutical industry.
Samantha has nearly twenty years of biopharmaceutical industry experience across Research, Translational Medicine and Clinical Development. Based in Cambridge, MA Samantha currently leads the Late Stage Unit accountable for the clinical development of Biogen’s Alzheimer’s disease, Dementia & Movement Disorders portfolios. Previously Samantha was at AstraZeneca where she held roles in the US, Canada and Sweden as Vice President of Translational Science & Global Program Lead in Alzheimer’s disease.
Samantha’s discovery and development experience spans multiple therapeutic modalities and Neurological indications including Alzheimer’s disease, dementias, movement disorders, pain and ophthalmology. Samantha has led the design and conduct of Alzheimer’s programs through early and late clinical stages, and in doing has been passionate about advancing the science on biomarkers, patient selection, diagnostics and disease stage. For her leadership in this area
Samantha was awarded the 2017 Fierce Women in Biotech Award. Samantha is a member of the World Dementia Council, and an executive member of the Board of The Boston Home.
Samantha’s Twitter profile @SLBHaeb
Soccer/Teen/Dog/Working mum. Lapsed distance runner. Biotech & science leader